Reinhard MD - Curis Senior Development

Curis Management Efficiency

The company has return on total asset (ROA) of (0.4597) % which means that it has lost $0.4597 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.7268) %, meaning that it created substantial loss on money invested by shareholders. Curis' management efficiency ratios could be used to measure how well Curis manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.73 in 2024. Return On Capital Employed is likely to drop to -0.8 in 2024. At this time, Curis' Total Assets are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 4.1 M in 2024, whereas Other Current Assets are likely to drop slightly above 1.7 M in 2024.

Similar Executives

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts. Curis operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 60 people. Curis Inc (CRIS) is traded on NASDAQ Exchange in USA. It is located in Building C, Lexington, MA, United States, 02421 and employs 49 people. Curis is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Curis Inc Leadership Team

Curis Stock Performance Indicators

Additional Tools for Curis Stock Analysis